360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Amicus Therapeutics Inc

Type: Company

Name: Amicus Therapeutics Inc

Nationality: United States

Web Address: http://www.amicustherapeutics.com/

First reported 2 hours ago - Updated 2 hours ago - 1 reports

Amicus Therapeutics Inc

Amicus Therapeutics Q1 net loss increases

3 minutes ago, 5:04am (ET) 05/23/2013 DatamonitorAmicus Therapeutics, a biopharmaceutical company, has reported that net loss attributable to common stockholders for the first quarter ended March 31, 2013 was $17.46 million, or $0.35 loss per share, compared ... [Published Zecco - 2 hours ago]

Entities: Amicus Therapeutics Inc

First reported 18 hours ago - Updated 18 hours ago - 1 reports

Form 8-K AMICUS THERAPEUTICS INC For: May 16

StreetInsider.com - Form 8-K AMICUS THERAPEUTICS INC For: May 16 ... [Published Street Insider - 18 hours ago]

Entities: Amicus Therapeutics Inc, 8-k

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Amicus Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript)

Amicus Therapeutics, Inc. (FOLD) 2013 UBS Global Healthcare Conference Call May 21, 2013 1:30 PM ETMatthew Roden - UBSGood evening everyone. My name is Matt Roden. I am one of biotech analyst here at UBS and I'd like to thank everyone for attending the ... [Published Seeking Alpha - May 22 2013]

Entities: Enzyme, Protein, Fabry Disease

First reported May 16 2013 - Updated May 16 2013 - 1 reports

AMICUS

Amicus Therapeutics: The Good And The Bad

Home » Blogs » Amicus Therapeutics (FOLD) is a biopharmaceutical company that is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. ... [Published BioPortfolio - May 16 2013]

Entities: Amicus Therapeutics Inc, Fabry Disease, AMICUS, Placebo

First reported May 14 2013 - Updated May 15 2013 - 3 reports

UBS AG

Amicus Therapeutics, Inc. (FOLD) to Present at UBS Global Healthcare Conference

Staying up-to-date has never been simpler. Sign up for the today! CRANBURY, N.J., May 14, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview ... [Published BioSpace - May 15 2013]

Entities: Amicus Therapeutics Inc, Healthcare Conference, UBS AG

First reported May 09 2013 - Updated May 10 2013 - 3 reports

Amicus' CEO Discusses Q1 2013 Results - Earnings Call Transcript

Amicus Therapeutics, Inc. (FOLD) Q1 2013 Results Earnings Call May 9, 2013 5:00 PM ETOperatorGood day, ladies and gentlemen. And welcome to the Amicus Therapeutics First Quarter 2013 Results Conference Call. At this time, all participants are in a listen-only ... [Published Seeking Alpha - May 10 2013]

Entities: AMICUS, Fabry Disease, Patient, Placebo, John Crowley

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Amicus Therapeutics (FOLD) Posts Quarterly Results

Amicus Therapeutics (NASDAQ: FOLD) released its earnings data on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.04, Analyst Ratings.Net reports.Shares of Amicus Therapeutics ... [Published American Banking News - May 10 2013]

Entities: Amicus Therapeutics Inc, lysosome, Neurodegeneration

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Amicus Therapeutics Announces First Quarter 2013 Financial Results and Corporate Updates

CONTACT: Investors/Media:Sara Pellegrinospellegrino@amicusrx.com(609) 662-5 ... [Published Reuters - May 09 2013]

Entities: Amicus Therapeutics Inc

First reported May 02 2013 - Updated May 02 2013 - 3 reports

Amicus Therapeutics to Announce First Quarter 2013 Financial. . .

Amicus Therapeutics to Announce First Quarter 2013 Financial Results on May 9, 2013GlobeNewswireCRANBURY, N.J., May 2, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Thursday, May ... [Published Equities.com - May 02 2013]

Entities: Amicus Therapeutics Inc, AMICUS, Cranbury (United States), Fabry Disease, lysosome

First reported Apr 24 2013 - Updated Apr 24 2013 - 1 reports

Form 8-K AMICUS THERAPEUTICS INC For: Apr 18

StreetInsider.com - Form 8-K AMICUS THERAPEUTICS INC For: Apr 18 ... [Published Street Insider - Apr 24 2013]

Entities: Amicus Therapeutics Inc, 8-k

First reported Feb 27 2013 - Updated Feb 27 2013 - 1 reports

Don't Fold On Amicus Therapeutics Just Yet

By Stephen Simpson : It's hard enough to pick winners in biotech, but when companies try to explain away bad trial data with "don't look at that, look at *this*" post hoc analysis, all manner of alarms and sirens should go off in investors' heads. ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 27 2013]

Entities: Amicus Therapeutics Inc, Biotechnology, Stephen Simpson, Drugs

First reported Feb 15 2013 - Updated Feb 15 2013 - 1 reports

Amicus Therapeutics' CEO Presents Lysosomal Disease Network WORLD Symposium Data Highlights Conference (Transcript)

Amicus Therapeutics, Inc. ( FOLD ) Lysosomal Disease Network WORLD Symposium Data Highlights Conference Call February 15, 2013, 11:30 am ET Executives Sara Pellegrino - Associate Director, Investor Relations John Crowley - Chairman & CEO David ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 15 2013]

Entities: Amicus Therapeutics Inc, John Crowley, Investor Relations

Quotes

...John F Crowley, Chairman and Chief Executive Officer of stated, "Amicus had a productive first quarter that was largely focused on the execution of clinical and regulatory activities for monotherapy for Fabry disease, our upcoming clinical studies in Fabry and Pompe, and the build out of our CHART platform. A Type C meeting with the FDA will take place during the second quarter to discuss the statistical analysis plan for while the 12-month data are still blinded. We remain on track to unblind and announce these 12-month results in the third quarter. We are also finalizing the design of our repeat-dose Phase 2b co-administration study for Pompe disease, which we expect to begin in the third quarter. Our strong financial position will continue to support the advancement of these programs as we approach several key milestones throughout the remainder of 2013."

Amicus Therapeutics Announces First Quarter 2013 Financial Results and Corporate Updates GlobeNew ... [Published Yahoo! Finance - May 09 2013]

...will provide even more benefits to employers, employees and professionals seeking new jobs," said Debbie Hart, President and CEO of BioNJ. "This Conference provides an excellent opportunity for Human Resource leaders to come togethertogether with other industry professionals to address the issues and trends currently affecting a biotech industry that is constantly facing new opportunities and challenges. This year’s Conference focuses on this very important topic of transition and transformation and the strategic role HR professionals play in driving that process. Our industry looks to these experts to manage these changes and create a culture that can thrive."

BioNJ To Host 2ND Annual Life Sciences Industry HR Conference on May 20 [Published Business Wire - Apr 30 2013]

John F Crowley, chairman and chief executive officer of Amicus stated, "The advancement of our core platform technology in Pompe and other lysosomal storage disorders is a continued great step forward for Amicus. Across these serious genetic diseases, we are leveraging this chaperone-ERT combination platform to work towards improving currently marketed ERTs and to develop our own proprietary next-generation ERTs that incorporate our small molecule chaperones. These chaperone stabilizers have the potential to enhance ERT activity and tissue uptake while also significantly reducing the immunogenicity of the ERTs. Through these programs we hope to offer new benefits and treatment options for patients with lysosomal storage diseases."

Amicus advances chaperone-ERT combination platform in Pompe disease [Published PharmaBiz - Feb 16 2013]

John F Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics said, "Study 013 was the first clinical study to investigate the chaperone-ERT combination approach. This study has been a major catalyst for our further development of chaperone-ERT combinations across the lysosomal storage diseases, including chaperones co-administered with marketed ERTs as well as proprietary chaperone-ERT co-formulated products in preclinical development as next-generation ERTs."

Amicus Therapeutics Presents Additional Results From Phase 2 Chaperone-Enzyme Replacement Therapy ... [Published Stockwatch - Feb 13 2013]

More Content

sort by: Date \| Relevance
Amicus Therapeutics Q1 net loss increases [Published Zecco - 2 hours ago]
Form 8-K AMICUS THERAPEUTICS INC For: May 16 [Published Street Insider - 18 hours ago]
Amicus Therapeutics' CEO Presents at 2013 UBS G... [Published Seeking Alpha - May 22 2013]
Amicus Therapeutics: The Good And The Bad [Published BioPortfolio - May 16 2013]
Amicus Therapeutics: The Good And The Bad [Published Seeking Alpha - May 15 2013]
Amicus Therapeutics, Inc. (FOLD) to Present at ... [Published BioSpace - May 15 2013]
Amicus Therapeutics, Inc. to Present at UBS Glo... [Published BioSpace - May 14 2013]
Amicus Therapeutics to Present at UBS Global He... [Published Reuters - May 14 2013]
Significant Near-Term Top-Line Data Catalyst An... [Published BioMedReports - May 14 2013]
Amicus Therapeutics to Present at UBS Global He... [Published GlobeNewswire: Acquisitions News - May 14 2013]
Amicus Therapeutics to Present at UBS Global He... [Published Nasdaq - May 14 2013]
Amicus' CEO Discusses Q1 2013 Results - Earning... [Published Seeking Alpha - May 10 2013]
Amicus Therapeutics (FOLD) Posts Quarterly Results [Published American Banking News - May 10 2013]
U.S./Canada daily earnings hits & misses May 9 ... [Published Globe and Mail - May 09 2013]
Amicus Therapeutics Announces First Quarter 201... [Published Yahoo! Finance - May 09 2013]
Amicus Therapeutics Announces First Quarter 201... [Published Reuters - May 09 2013]
Amicus Therapeutics Announces First Quarter 201... [Published GlobeNewswire - May 09 2013]
Amicus Therapeutics to Announce First Quarter 2... [Published Equities.com - May 02 2013]
Amicus Therapeutics to Announce First Quarter 2... [Published OSIX News - May 02 2013]
Amicus Therapeutics to Announce First Quarter 2... [Published Stockwatch - May 02 2013]
Amicus Therapeutics to Announce First Quarter 2... [Published GlobeNewswire: Acquisitions News - May 02 2013]
BioNJ To Host 2ND Annual Life Sciences Industry... [Published Business Wire - Apr 30 2013]
Form 8-K AMICUS THERAPEUTICS INC For: Apr 18 [Published Street Insider - Apr 24 2013]
Amicus Therapeutics to Present at 12th Annual N... [Published GlobeNewswire: Acquisitions News - Apr 24 2013]
Amicus Therapeutics Director Buys 25K Shares an... [Published Wall St. Cheat Sheet - Mar 19 2013]
FDA's New "Breakthrough" Designation Allows New... [Published Marketwire - Breaking News Releases - Mar 13 2013]
8-K - AMICUS THERAPEUTICS INC (0001178879) (Filer) [Published SEC Filings - Mar 12 2013]
Amicus Therapeutics Announces Full-Year 2012 Fi... [Published GlobeNewswire: Acquisitions News - Mar 12 2013]
Amicus Therapeutics to Announce Full-Year 2012 ... [Published GlobeNewswire: Acquisitions News - Mar 07 2013]
Amicus Therapeutics Introduces Proprietary "CHA... [Published GlobeNewswire: Acquisitions News - Mar 04 2013]

Blogs

sort by: Date \| Relevance
Amicus Therapeutics Director Buys 25K Shares an... [Published Wall St. Cheat Sheet - Mar 19 2013] Sol J Barer, who is Director at Amicus Therapeutics ( NASDAQ:FOLD ), bought 25,000 shares at $3.40 per share for a total value of $85,000. The shares recently traded at $3.45, up $0.05, or 1.47% since the insider buy. Dow 15,000? S&P 1,600? Searching ...
Orphan Drugs: Making Rare Diseases Rarer [Published I Am Biotech - Feb 25 2013] A panel at the BIO CEO & Investor Conference provided an analysis of the thriving orphan drug market opportunity featuring industry, clinical and regulatory experts specializing in rare diseases. The signing of FDASIA by President Obama in July ...
4 Healthcare Stock Stories Starting Off the Sho... [Published Wall St. Cheat Sheet - Feb 19 2013] Novartis ( NYSE:NVS ): Closing price $69.20 Chairman Daniel Vasella will receive a package that might reach $78 million upon his exit, if he abides by a non-compete agreement that disallows him from working for Novartis’s rivals. Via an emailed ...
Stone Energy Downgraded to Accumulate and 3 Dow... [Published Wall St. Cheat Sheet - Dec 20 2012] Wall St. Watchdog reveals information about companies for which stock analysts downgraded the shares on December 20th. Stone Energy ( NYSE:SGY ): Global Hunter Securities downgraded its rating on this company from Buy to Accumulate and changed ...
Amicus & GlaxoSmithKline Report Study 011 Resul... [Published Wall St. Cheat Sheet - Dec 19 2012] On Wednesday, Amicus Therapeutics ( NASDAQ:FOLD ) and GlaxoSmithKline ( NYSE:GSK ) reported the 6-month primary treatment period results from the first Phase 3 global registration study (Study 011) of investigational oral migalastat HCl monotherapy ...

Audio/Video

sort by: Date \| Relevance
Orphan Drugs: Making Rare Disease Rarer [Published BIO Channel - YouTube - Feb 27 2013]
Orphan Drugs: Making Rare Disease Rarer [Published BIO Channel - YouTube - Feb 20 2013]

Press Releases

sort by: Date \| Relevance
Amicus Therapeutics to Present at UBS Global He... [Published GlobeNewswire: Acquisitions News - May 14 2013]
Amicus Therapeutics to Announce First Quarter 2... [Published GlobeNewswire: Acquisitions News - May 02 2013]
BioNJ To Host 2ND Annual Life Sciences Industry... [Published Business Wire - Apr 30 2013]
Amicus Therapeutics to Present at 12th Annual N... [Published GlobeNewswire: Acquisitions News - Apr 24 2013]
FDA's New "Breakthrough" Designation Allows New... [Published Marketwire - Breaking News Releases - Mar 13 2013]